Global Acute Coronary Syndrome API Manufacturers, Marketed and Phase III Drugs Landscape Report 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 13, 2019--The “Acute Coronary Syndrome - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Acute Coronary Syndrome - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019″ report provides comprehensive insights about marketed and Phase III products for Acute Coronary Syndrome . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.
Global API Manufacturers of Marketed Products for Acute Coronary Syndrome
Coverage of API manufacturers for Acute Coronary Syndrome marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.
Emerging Phase III products for Acute Coronary Syndrome
This report provides a comprehensive understanding of the emerging Phase III therapies for Acute Coronary Syndrome which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2021.
ScopeA review of the marketed products for Acute Coronary Syndrome including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2021 and API manufacturer details. Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details API manufacturers for the marketed products with location details Emerging Phase III product profiles for Acute Coronary Syndrome including product description, developmental activities, licensors & collaborators and chemical information
Reasons to BuyAPI intelligence for marketed drugs for the indication and gaining insights of API manufacturers Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space
Key Topics Covered:
1. Report Introduction
2. Acute Coronary Syndrome: OverviewRisk Factors Causes Symptoms Pathophysiology Prognosis Diagnosis Treatment
3. Comparative Analysis of Marketed and Emerging Products
4. Marketed TherapiesProduct Description Route of Synthesis Mechanism of Action Pharmacology Pharmacodynamics Pharmacokinetics Adverse Reactions Clinical Trials Regulatory Milestones Product Development Activities Product Details United States Europe Global Sales Assessment Historical Global Sales Forecasted Global Sales Patent Details
5. Emerging Therapies (Phase III)Product Description Research and Development Product Development Activities Forecasted Global Sales
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/cbl2s4/global_acute?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190213005289/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/13/2019 04:59 AM/DISC: 02/13/2019 04:59 AM